
A cost-effective EDC system for Phase I, IV, and med device trials, offering flexible data capture, management, and analysis capabilities.
Vendor
Medidata
Company Website
Rave Lite is a streamlined version of Medidata's Rave EDC system, designed specifically for Phase I, Phase IV, feasibility, and post-market medical device studies. It provides essential data capture, management, and basic analysis functionalities with a flexible pricing structure, making it an ideal solution for trials with specific budgetary and functional requirements.
Key Features
Focused EDC Functionality Rave Lite offers core Electronic Data Capture capabilities tailored for specific trial types.
- Data capture for Phase I, IV, and med device studies
- Data management tools
- Basic data analysis features
Cost-Effective Solution Rave Lite provides a more affordable option for clinical trials with specific needs.
- Adaptable pricing structure
- Pay only for required functionalities
- Suitable for various budget constraints
Scalable Platform The system can grow and adapt as trial requirements change.
- Ability to scale up functionality as needed
- Flexibility to pivot based on study growth
Accelerated Study Build Rave Lite streamlines the process of setting up clinical trials.
- Pre-configured and pre-validated system
- Faster and more accurate study-building
- Accelerated implementation process
Benefits
Optimized Resource Allocation Rave Lite allows for more efficient use of trial budgets.
- Invest only in necessary technology
- Avoid paying for unused features
- Tailor technology to specific trial needs
Familiar User Experience Users can leverage their existing knowledge of Rave EDC.
- Reduced learning curve for experienced Rave users
- Consistent interface across Medidata products
- Easier adoption for clinical trial teams
Improved Study Efficiency The streamlined nature of Rave Lite can lead to faster study execution.
- Quicker study build and setup
- Focused functionality reduces complexity
- Potential for shorter timelines in early and late-stage trials